All PlansCoverageLow impact
Aspirin Resistance Testing
Blue Cross & Blue Shield of Mississippi·MS · Cardiology, Internal Medicine, Family Medicine +1 more·Medical Policy
Effective date
Nov 5, 2025
We identified it
Jun 20, 2026
Summary
This policy update confirms that aspirin resistance testing remains classified as investigational and not covered. The policy was reviewed with no changes to the coverage determination, maintaining that CPT 84431 (thromboxane metabolite testing) is not considered medically necessary.
Action Required
Immediately: Billing team should ensure CPT 84431 (thromboxane metabolite testing) continues to be flagged as non-covered investigational in billing system. Deny prior authorization requests and inform providers this test remains investigational. Claims for this code will be denied.